Nanomedicines are emerging as an innovative technology in the scientific field, as they help address unmet medical needs and offer alternatives for many therapeutic areas.
Nanomedicine uses state-of-the-art nanotechnology like nanoparticles, nanorobots or nanoelectronic biosensors for diagnosing or treating cancer, cardiovascular, and neurodegenerative diseases.
However, a number of issues related to the regulatory framework raise more questions than answers while critics suggest that without an EU-centralised approach, the potential of nanomedicines will remain untapped.
Nanotechnology has contributed to the production of vaccines against the COVID-19 virus. However, in Europe, a de-centralised and vague regulatory framework prevents nanomedicines from harnessing their full potential to save lives.
The European Parliament will put pressure on the Commission and the member states to provide the necessary regulatory framework for nanomedicines in order to better make use of their potential for patients, EU lawmaker Pietro Fiocchi told EURACTIV in an interview.
The EU’s Pharmaceutical Strategy must do more to support nanomedicines and protect patient safety. Here’s why.
Mike Isles is the Executive Director of the European Alliance for Access to Safe Medicines (EAASM).
If Europe is to make its world-leading pharmaceutical sector fit …